Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riluzole plus methylprednisolone versus methylprednisolone plus placebo for acute thoracolumbar spinal cord injury
IRCT20240722062515N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spinal cord injury (SCI) and thoracolumbar fracture comparing Riluzole + methylprednisolone with Placebo + methylprednisolone (2 arms). Primary endpoints: Functional recovery, Frankel scale and 11 more. Started Sep 2024; status: completed.
02
Drugs
riluzolemethylprednisolone
03
Conditions
spinal cord injury (SCI)thoracolumbar fracture
Beyond the preview
Go deeper on IRCT20240722062515N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240722062515N1.